<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Neurosci</journal-id>
<journal-id journal-id-type="hwp">jneuro</journal-id>
<journal-id journal-id-type="pmc">jneurosci</journal-id>
<journal-id journal-id-type="publisher-id">J. Neurosci</journal-id>
<journal-title-group>
<journal-title>The Journal of Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">0270-6474</issn>
<issn pub-type="epub">1529-2401</issn>
<publisher>
<publisher-name>Society for Neuroscience</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27605603</article-id>
<article-id pub-id-type="pmc">5013180</article-id>
<article-id pub-id-type="publisher-id">JN-TS-1333–16</article-id>
<article-id pub-id-type="doi">10.1523/JNEUROSCI.1333-16.2016</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>TechSights</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Resolving Behavioral Output via Chemogenetic Designer Receptors Exclusively Activated by Designer Drugs</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Burnett</surname>
<given-names>C. Joseph</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Krashes</surname>
<given-names>Michael J.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<aff id="aff1"><sup>1</sup>Diabetes, Endocrinology and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, </aff>
<aff id="aff2"><sup>2</sup>National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, and </aff>
<aff id="aff3"><sup>3</sup>Brown University–National Institutes of Health Graduate Partnerships Program, Providence, Rhode Island 02912</aff>
</contrib-group>
<author-notes>
<corresp>Correspondence should be addressed to Michael J. Krashes at the above address.
<email>michael.krashes@nih.gov</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<day>7</day>
<month>9</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>7</day>
<month>3</month>
<year>2017</year>
</pub-date>
<!-- PMC Release delay is 6 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>36</volume>
<issue>36</issue>
<fpage>9268</fpage>
<lpage>9282</lpage>
<history>
<date date-type="received">
<day>5</day>
<month>4</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>29</day>
<month>6</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>7</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2016 the authors 0270-6474/16/369268-15$15.00/0</copyright-statement>
<copyright-year>2016</copyright-year>
</permissions>
<self-uri xlink:href="zns03616009268.pdf" xlink:title="pdf" xlink:type="simple"></self-uri>
<abstract>
<p>Designer receptors exclusively activated by designer drugs (DREADDs) have proven to be highly effective neuromodulatory tools for the investigation of neural circuits underlying behavioral outputs. They exhibit a number of advantages: they rely on cell-specific manipulations through canonical intracellular signaling pathways, they are easy and cost-effective to implement in a laboratory setting, and they are easily scalable for single-region or full-brain manipulations. On the other hand, DREADDs rely on ligand–G-protein-coupled receptor interactions, leading to coarse temporal dynamics. In this review we will provide a brief overview of DREADDs, their implementation, and the advantages and disadvantages of their use in animal systems. We also will provide numerous examples of their use across a broad variety of biomedical research fields.</p>
</abstract>
<kwd-group>
<kwd>behavior</kwd>
<kwd>cell-type specificity</kwd>
<kwd>chemogenetics</kwd>
<kwd>DREADD</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>